Initial Clinical Experience With the MONARCH Platform, Urology for the Treatment of Kidney Stones
Study Details
Study Description
Brief Summary
The purpose of this study is to collect descriptive performance data using the MONARCH Platform, Urology (a novel robotic device) to perform mini-percutaneous nephrolithotomy (kidney stone removal) procedures. Data gathered from this study will be used to optimize the robotic platform and inform training and education material for the future users.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Robotic-assisted mini-Percutaneous Nephrolithotomy (PCNL) Participants with kidney stones will be enrolled for robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter for visualization and access to the urinary tract for diagnostic and therapeutic procedures. |
Device: Robotic-assisted mini-PCNL
Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
|
Outcome Measures
Primary Outcome Measures
- Percentage of Robotic-assisted mini-Percutaneous Nephrolithotomy (PCNL) Procedures Completed [Procedure Visit (Day 0)]
The percentage of Robotic-assisted mini-PCNL procedures that are successfully completed. Completion is defined as: (1) gained safe concomitant (that is, retrograde and antegrade) access to the upper urinary tract, (2) located and visualized kidney stones, (3) enabled fragmentation of stones by standard of care method, and (4) evacuated stone fragments and dust.
Secondary Outcome Measures
- Number of Adverse Events [Up to 30 days, Post-operative (Day 30)]
Adverse events are defined as any undesirable clinical occurrence in a participant, whether or not it is considered to be device-related. All adverse events will be reported.
- Number of Procedures Converted to Conventional Methods (Ureteroscopy or Percutaneous Nephrolithotomy) [Procedure Visit, Day 0]
Number of procedures converted to conventional methods (ureteroscopy or percutaneous nephrolithotomy) for any reason will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Simple renal caliceal and/or pyelo stone(s), greater than or equal to (>=) 10 millimeter in size identified on computerized tomography (CT) scan, and appropriate for Percutaneous nephrolithotomy (PCNL) treatment according to American Urological Association (AUA) guidelines
-
Normal upper tract anatomy, amenable to PCNL and ureteroscopy
-
Body mass index less than (<) 40 kilogram-meter squared
-
Participants with a percutaneous tract length <15 centimeter as measured by the estimation of the skin to stone or skin to appropriate calyx for treatment through a CT scan
-
Participant is an appropriate candidate for a mini-PCNL based on the clinical guidelines and investigator assessment
Pre-Operative Exclusion Criteria:
-
Any medical or physical condition/limitation that would contraindicate a conventional ureteroscopy or PCNL [for example, atypical interposition of visceral organs (bowel, spleen, or liver)] in the supine position. This assessment will be made by the investigator team
-
Participation in any other clinical trial 30-days before and throughout the duration of the study that might impact the results
-
A solitary functioning kidney
-
Female subjects who are pregnant or nursing or those of childbearing potential refusing a pregnancy test
-
Presence of ureteral impacted stones
-
Presence of ureteral obstruction
-
Presence of untreated urinary tract infection, urosepsis
-
Inability to give consent
-
Presence of a renal mass which has not been investigated
-
Staghorn stone
-
Participant has an electrically or magnetically activated implanted medical device
-
Significant pharmacological anticoagulant therapy or uncorrected bleeding diathesis
-
Tumor in the probable access tract area and potential malignant renal tumor
Intra-Procedure Exclusion Criteria:
- Any presenting condition discovered intra procedurally that in the opinion of the investigator would make participating in this study not in the participant's best interest. For example, participants no longer considered good candidates for a mini-PCNL procedure for the removal of the kidney stones.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California - Irvine Medical Center | Orange | California | United States | 92868 |
Sponsors and Collaborators
- Auris Health, Inc.
Investigators
- Principal Investigator: Jaime Landman, MD, University of California, Irvine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-URO-0001
- 2021-URO-0001